#United States #New York #Briya #AIRE #AI Research Platform

Briya Launches Free Access to AIRE™

In a significant move for the global scientific community, Briya has announced the launch of AIRE™, an AI-powered conversational platform that enables researchers to conduct medical research without incurring costs. This development marks a milestone in the accessibility of advanced research capabilities and aims to facilitate clinical, epidemiological, and real-world evidence inquiries for professionals across the globe.

Briya's AIRE™ stands apart from traditional AI systems by focusing specifically on the nuances of scientific research. As David Lazerson, Co-founder and CEO of Briya, aptly put it, "Researchers don't need more disjointed tools or generic AI lacking scientific context; they require accessible environments tailored to understanding health data, revealing insights, and generating trustworthy evidence."

What is AIRE™?

AIRE™ serves as an essential bridge, connecting fragmented healthcare data with robust AI models aimed at producing trustworthy scientific evidence. By utilizing this platform, researchers can:

• - Design and simulate cohorts
• - Validate endpoints
• - Analyze treatment pathways
• - Conduct chart reviews
• - Identify gaps in methodologies
• - Extract clinical insights from unstructured narratives

This is all achievable through a user-friendly conversational interface that keeps scientific oversight in the hands of the researcher, truly embodying a researcher-in-the-loop paradigm. The platform is browser-based, allowing widespread accessibility for those engaged in health research.

A Shift in Research Methodology

The announcement of AIRE™ signals a broader trend towards more democratized access within professional AI markets. Briya is drawing parallels to other popular platforms in AI, such as OpenAI and Copilot, which have demonstrated how free-access offerings can drive adoption and engagement.

Briya's free-access model is designed to usher in a new era in health and biomedical research, which has conventionally been dominated by sizable academic medical centers and pharmaceutical companies, making such advanced analytical capabilities less accessible to smaller research institutions.

Importance of Transparency and Rigor

In a time when scientific research faces intense scrutiny regarding credibility and validity, AIRE™ introduces transparency at its core. Unlike general AI tools, AIRE™ combines epidemiological methodologies with clear reasoning and evidence generation that researchers can trust. Users can now engage directly with reputable public health datasets, including resources from the CDC, while implementing well-established epidemiological methods.

Such accessibility to credible datasets empowers researchers, sparking a much-needed shift towards efficient evidence generation that is essential for progress in the field. The pressure to accelerate discovery in healthcare shares a symbiotic relationship with the tight budgets and growing analytical complexity many researchers face today.

Testimonials from Early Users

Early users from academia have quickly recognized the value of AIRE™. Researchers have reported that the platform assists them in uncovering larger research populations from unstructured data, promoting a faster evidence generation process and minimizing the barriers between data inquiry and scientific insight.

Prominent figures such as Prof. Robert S. Brown, Jr. from Weill Cornell Medicine have lauded the potential of AIRE™ to transform medical practices by streamlining the synthesis of clinical evidence—a crucial facet of medical decision-making.

Future Plans for Enhanced Features

While AIRE™ is now publicly available for free use, Briya is also preparing to offer premium access for $25 monthly. This will include further analytical capabilities and the ability to access harmonized EMR datasets under a separate subscription plan, enhancing the overall user experience for deeper, publication-grade exploratory analysis.

Prof. Jonathan Samet, Briya's newly appointed Chief Epidemiologist, highlighted the potential of AI in epidemiological and public health research, stating, "Questions that once required substantial resources can increasingly be explored by a broader spectrum of researchers. Lowering barriers to generating evidence is key to accelerating discoveries that can improve population health."

Briya is committed to facilitating this advancement in scientific research and invites researchers to experience AIRE™ at briya.com/briya-aire-signup now.

About Briya

Briya is a health technology firm focused on supporting essential medical and biopharma research and innovation through AI and data. The AIRE™ platform, designed specifically for clinical and biomedical inquiries, acts as an AI assistant that can efficiently gather and analyze intricate clinical data. Briya prioritizes security, compliance, and trust while aiming to expedite research discoveries and advances.

For more updates, connect with Briya on LinkedIn and X or visit briya.com.